135 related articles for article (PubMed ID: 18236715)
21. [Dibromodulcitol in combination with actinotherapy of spinocellular carcinoma].
Petruzelka L; Konopásek B; Betka J; Klozar J; Kvapil F; Mazánek J; Růzicka V; Prokes K
Sb Lek; 1984 Sep; 86(8-9):259-64. PubMed ID: 6505608
[No Abstract] [Full Text] [Related]
22. Systemic therapies for squamous cell carcinoma of the head and neck.
Kurtin SE
Semin Oncol Nurs; 2009 Aug; 25(3):183-92. PubMed ID: 19635397
[TBL] [Abstract][Full Text] [Related]
23. Is immunohistochemical epidermal growth factor receptor expression overestimated as a prognostic factor in head-neck squamous cell carcinoma? A retrospective analysis based on a tissue microarray of 365 carcinomas.
Fischer C; Zlobec I; Stöckli E; Probst S; Storck C; Tornillo L; Lugli A; Wolfensberger M; Terracciano L
Hum Pathol; 2008 Oct; 39(10):1527-34. PubMed ID: 18620726
[TBL] [Abstract][Full Text] [Related]
24. Controversies surrounding the use of neoadjuvant chemotherapy in locally advanced head and neck cancer.
Giralt J; Benavente S
Expert Rev Anticancer Ther; 2008 Sep; 8(9):1359-63. PubMed ID: 18759687
[No Abstract] [Full Text] [Related]
25. Chemokines and squamous cancer of the head and neck: targets for therapeutic intervention?
Yeudall WA; Miyazaki H
Expert Rev Anticancer Ther; 2007 Mar; 7(3):351-60. PubMed ID: 17338654
[TBL] [Abstract][Full Text] [Related]
26. Current state-of-the-art for concurrent chemoradiation.
Bernier J
Semin Radiat Oncol; 2009 Jan; 19(1):3-10. PubMed ID: 19028339
[TBL] [Abstract][Full Text] [Related]
27. Organ and function preservation: the role of surgery as the optimal primary modality or as salvage after chemoradiation failure.
Scher RL; Esclamado RM
Semin Radiat Oncol; 2009 Jan; 19(1):17-23. PubMed ID: 19028341
[TBL] [Abstract][Full Text] [Related]
28. Distinctive E-cadherin and epidermal growth factor receptor expression in metastatic and nonmetastatic head and neck squamous cell carcinoma: predictive and prognostic correlation.
Muller S; Su L; Tighiouart M; Saba N; Zhang H; Shin DM; Chen Z
Cancer; 2008 Jul; 113(1):97-107. PubMed ID: 18473353
[TBL] [Abstract][Full Text] [Related]
29. Impact of tumor board recommendations on treatment outcome for locally advanced head and neck cancer.
Nguyen NP; Vos P; Lee H; Borok TL; Karlsson U; Martinez T; Welsh J; Cohen D; Hamilton R; Nguyen N; Nguyen LM; Vinh-Hung V
Oncology; 2008; 75(3-4):186-91. PubMed ID: 18841033
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma.
Hama T; Yuza Y; Saito Y; O-uchi J; Kondo S; Okabe M; Yamada H; Kato T; Moriyama H; Kurihara S; Urashima M
Oncologist; 2009 Sep; 14(9):900-8. PubMed ID: 19726454
[TBL] [Abstract][Full Text] [Related]
31. Multimodal treatment for head and neck cancer.
Lango MN
Surg Clin North Am; 2009 Feb; 89(1):43-52, viii. PubMed ID: 19186230
[TBL] [Abstract][Full Text] [Related]
32. Effect of bortezomib on EGFR expression in head and neck squamous cell carcinoma cell lines.
Wagenblast J; Hambek M; Baghi M; Knecht R
Anticancer Res; 2008; 28(2A):687-92. PubMed ID: 18507008
[TBL] [Abstract][Full Text] [Related]
33. Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.
Modjtahedi H; Essapen S
Anticancer Drugs; 2009 Nov; 20(10):851-5. PubMed ID: 19826350
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy in head and neck cancer.
Armand JP; Couteau C
Eur J Cancer; 1995; 31A(5):819-22. PubMed ID: 7640066
[No Abstract] [Full Text] [Related]
35. Epidermal growth factor receptor as a target in cancer therapy.
Kim ES
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S87-95. PubMed ID: 19795581
[TBL] [Abstract][Full Text] [Related]
36. Postoperative reduced dose of cisplatin concomitant with radiation therapy in high- risk head and neck squamous cell carcinoma.
Franchin G; Minatel E; Politi D; Gobitti C; Talamini R; Vaccher E; Savignano MG; Trovo M; Sulfaro S; Barzan L
Cancer; 2009 Jun; 115(11):2464-71. PubMed ID: 19280588
[TBL] [Abstract][Full Text] [Related]
37. Prediction of chemosensitivity using multigene analysis in head and neck squamous cell carcinoma.
Hasegawa Y; Goto M; Hanai N; Ijichi K; Terada A; Hyodo I; Ogawa T; Fukushima M
Oncology; 2007; 73(1-2):104-11. PubMed ID: 18337622
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
Brizel DM; Murphy BA; Rosenthal DI; Pandya KJ; Glück S; Brizel HE; Meredith RF; Berger D; Chen MG; Mendenhall W
J Clin Oncol; 2008 May; 26(15):2489-96. PubMed ID: 18487568
[TBL] [Abstract][Full Text] [Related]
39. Dysphagia after chemoradiotherapy for head-and-neck squamous cell carcinoma: dose-effect relationships for the swallowing structures.
Dirix P; Abbeel S; Vanstraelen B; Hermans R; Nuyts S
Int J Radiat Oncol Biol Phys; 2009 Oct; 75(2):385-92. PubMed ID: 19553033
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of concurrent chemoradiotherapy with S-1 plus cisplatin in patients with unresectable locally advanced squamous cell carcinoma of the head and neck: Japan Clinical Oncology Group Study (JCOG0706).
Nakamura K; Tahara M; Kiyota N; Hayashi R; Akimoto T; Fukuda H; Fujii M; Boku N
Jpn J Clin Oncol; 2009 Jul; 39(7):460-3. PubMed ID: 19429640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
